Nuwiq
(turoctocog alfa)PreclinicalSmall molecule
Novo NordiskTuroctocog alfa is used to treat and prevent bleeding in people with hemophilia A, a genetic disorder where the blood cannot clot properly.[1] Nuwiq is currently being investigated across 1 indication[3], with its most advanced program in Preclinical.[1]
Nuwiq is one of 20 small molecule programs targeting Hemophilia A. It is currently in Preclinical.
1
Indications
30
Total Trials
3
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
35 competitors in Hemophilia a
#DrugCompanyPhaseTrials
1Hemlibra
RocheApproved
Rayos
RRoxane Laboratories
Approved
Cyklokapron
JJ Molner
Approved
Efanesoctocog Alfa
SanofiPhase 3
Advate
TakedaPhase 3
Marstacimab
PfizerPhase 3
Qfitlia
GGenzyme, a Sanofi Company
Phase 3
Rfviia
RochePhase 3
PF-06741086
PfizerPhase 3
SCT800
SSinocelltech Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Haemophilia A14 trials
Show 11 more trials
Safety and Efficacy8 trials
Show 5 more trials
Efficacy and Safety2 trials
Immune Tolerance1 trial
4 more indications
Haemophilia A Without Inhibitors1 trial
Side Effects1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for turoctocog alfa. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Coagulation Factor VIII Exogenous Protein[2]
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company